•  •  Dark Mode

Your Interests & Preferences

I am a...

law firm lawyer
in-house company lawyer
litigation lawyer
law student
aspiring student

Website Look & Feel

 •  •  Dark Mode
Blog Layout

Save preferences

AZB, SAM, Tatva act on Infy co-founder Raghavan’s Indegene $200m healthtech sale to Carlyle, Brighton

Brighton Park Capital and Indegene, the Bangalore-headquartered enterprise healthtech solutions provider, today announced that Carlyle and Brighton Park Capital will acquire minority stakes in the company for US$200 million. The transaction, which is subject to customary regulatory approvals, consists of a secondary sale from existing shareholders of Indegene and a primary investment into the company.

— press release by Carlyle

AZB & Partners advised selling shareholder Nadathur Fareast Pte Ltd, the investment fund founded by Infosys co-founder NS Raghavan, led by a team of partners Sai Krishna Bharathan and Vivek Bajaj, senior associate Samyuktha Santhosh.

Update 18 May 2021: Shardul Amarchand Mangaldas advised Carlyle led by a team including partner Abhishek Guha, principal associate Tanya Uppal, senior associate Keegan Pavrey and associate Amrita Ghosh.

Update 18 May 2021: Tatva Legal advised Indegene Private Limited and the promoters led by a team including partner Manav Nagaraj, KS partner Bhargava, and lawyers Smita Rakshale and Mithila Hari as the core transaction team with support from partner Rashmi Talukdar, and lawyers Narayanan H, Junaid Ahmed and Krithika Chandra on the vendor due diligence.


Deal value: USD 200 million / INR 14.58 billion

This deal report is based on a firm's press release and may be only partially complete. Some firms or names of advisers may be therefore be missing.

Click to show 4 comments
at your own risk
By reading the comments you agree that they are the (often anonymous) personal views and opinions of readers, which may be biased and unreliable, and for which Legally India therefore has no liability. If you believe a comment is inappropriate, please click 'Report to LI' below the comment and we will review it as soon as practicable.